RANIBIZUMAB Pharmacologic Class Indexing
- Class set ID
- abb7b869-2738-4dc8-a98e-e06f93a1b135
- Version
- 3
- Effective date
- 20180813
- Type
- Indexing - Pharmacologic Class
Mapped DailyMed Labels#
Label, Manufacturer, Effective table| Label | Manufacturer | Effective | SPL version |
|---|
| These highlights do not include all the information needed to use BYOOVIZ safely and effectively. See full prescribing information for BYOOVIZ. BYOOVIZ ® (ranibizumab-nuna) injection, for intravitreal use Initial U.S. Approval: 2021 BYOOVIZ (ranibizumab-nuna) is biosimilar 1 to LUCENTIS (ranibizumab injection) 1 - Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there a | BIOGEN INC. | Samsung Bioepis Co., Ltd. | 20251201 | 14 |
| These highlights do not include all the information needed to use BYOOVIZ safely and effectively. See full prescribing information for BYOOVIZ. BYOOVIZ ® (ranibizumab-nuna) injection, for intravitreal use Initial U.S. Approval: 2021 BYOOVIZ (ranibizumab-nuna) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences be | Harrow Eye, LLC | Samsung Bioepis Co., Ltd. | 20251126 | 1 |
| These highlights do not include all the information needed to use LUCENTIS safely and effectively. See full prescribing information for LUCENTIS. LUCENTIS ® (ranibizumab injection) for intravitreal injection Initial U.S. Approval: 2006 | Genentech, Inc. | Roche Singapore Technical Operations Pte. Ltd. | 20251121 | 27 |
| These highlights do not include all the information needed to use SUSVIMO safely and effectively. See full prescribing information for SUSVIMO. SUSVIMO ® (ranibizumab injection) for intravitreal use via SUSVIMO ocular implant Initial U.S. Approval: 2006 | Genentech, Inc. | Roche Singapore Technical Operations Pte. Ltd | Genentech, Inc. (Hillsboro) | Roche Diagnostics GmbH | 20251121 | 14 |
| These highlights do not include all the information needed to use CIMERLI safely and effectively. See full prescribing information for CIMERLI. CIMERLI™ (ranibizumab-eqrn) injection, for intravitreal use Initial U.S. Approval: 2022 CIMERLI (ranibizumab-eqrn) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences bet | Coherus BioSciences Inc | 20250507 | 12 |
| These highlights do not include all the information needed to use CIMERLI safely and effectively. See full prescribing information for CIMERLI. CIMERLI ® (ranibizumab-eqrn) injection, for intravitreal use Initial U.S. Approval: 2022 CIMERLI (ranibizumab-eqrn) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences be | Sandoz Inc | 20240617 | 3 |